Articles tagged with Positron Emission Tomography
A new molecular imaging method using PET/CT with Gallium-68 DOTATATE identifies hormonally active tissues, allowing clinicians to re-evaluate patient management. This technique changes treatment plans in over 35% of patients, saving them from unnecessary surgeries.
Researchers have made significant breakthroughs in Alzheimer's disease detection using molecular imaging technology, which can identify beta-amyloid plaques in the brain. Studies show that high levels of amyloid binding are associated with an 80% chance of developing Alzheimer's disease within two years.
Piramal Imaging will present data from five florbetaben studies, including a pivotal Phase III trial that will provide the basis for regulatory submission later this year. The company is developing an innovative and proprietary tracer portfolio to address major clinical needs in Alzheimer's disease and other conditions.
Researchers have identified a new way to predict the risk of sudden cardiac arrest by imaging nerve function in the heart. A study involving 204 patients with advanced heart disease found that those with at least 38% denervated myocardium were at highest risk of sudden cardiac arrest.
SPECT/CT scans have been shown to change clinical management in thyroid cancer patients by improving staging and risk stratification. The technology has been used both post-operatively and pre-ablation to identify metastatic lesions and adjust treatment approaches, leading to avoidance of unnecessary therapy.
A new human study suggests that dopamine levels in the brain play a crucial role in determining how hard people work. Individuals with higher dopamine activity in certain areas showed greater motivation and effort, while those with increased dopamine in other areas were less likely to exert effort.
A new method using florbetaben PET scans may help diagnose Alzheimer's disease earlier by detecting beta-amyloid plaques in the brain. The study found a sensitivity of 77% and specificity of 94% compared to post-mortem diagnosis, with even higher accuracy for visual assessments.
A study published in The Journal of Neuroscience found that primitive brain structures activate before neocortex when individuals regain consciousness after general anesthesia. This discovery provides new insights into the emergence of consciousness and its relationship with brain function.
A PET imaging agent has been shown to reverse neurotoxicity and improve motor skills and memory in animal models of Parkinson's disease. The compound works as a scavenger of peroxynitrite, reducing neuronal death and promoting revival of neuronal function.
A study by UCLA's Jonsson Comprehensive Cancer Center found that early Positron Emission Tomography (PET) response after neoadjuvant chemotherapy is associated with increased survival in patients with soft tissue sarcomas. Patients who showed a significant PET response had significantly longer survival rates compared to those who did not.
Photoacoustic tomography allows scientists to see deep beneath the skin with high contrast, revealing tissue oxygen use and cancer biomarkers. The technique enables non-invasive imaging for breast cancer staging, early chemotherapy response monitoring, melanoma detection, and gastrointestinal tract visualization.
Imaging amino acid transporters with PET/CT has significantly altered management plans for 41% of patients with brain tumors, according to research. The imaging modality has improved detection of primary and recurrent high- and low-grade brain tumors, leading to changes in treatment from 'watch and wait' to chemotherapy or vice versa.
The new hybrid scanner combines MRI and PET technology to capture minute details and produce superior three-dimensional images. It will be used to diagnose cardiovascular disease, neurological diseases, mental health, and cancer more accurately and efficiently.
The Massachusetts Life Sciences Center awarded Dana-Farber Cancer Institute a $10 million grant to support the expansion of its pioneering cancer imaging research program. The new facility will enable better diagnosis, targeted therapies, and improved patient outcomes.
A new review of imaging studies confirms that positron emission tomography (PET) safely and accurately detects dementia, including the most common form among the elderly, Alzheimer's disease. The study found that combining PET with a biomarker called 18F-FDG can pinpoint key areas of metabolic decline in the brain indicating dementia.
A new PET technique using FLT-PET has shown highly sensitive imaging for patients with mantle cell lymphoma, a relatively rare and devastating blood cancer. The study found that all cancerous lesions were very highly visible using FLT-PET, providing a powerful biomarker for MCL.
Researchers from the University of Edinburgh developed an imaging technique using positron emission tomography (PET) scans to predict which patients need open heart surgery. The study found that inflammation and calcification processes are key factors in aortic stenosis, offering new hope for treatments.
Researchers have discovered a new marker that can accurately diagnose Alzheimer's disease versus frontotemporal lobar degeneration (FTLD), two types of dementia sharing similar symptoms. The PIB PET scan outperformed the FDG scan in differentiating between the two conditions, with higher sensitivity and accuracy.
A new chemical process developed by Harvard researchers simplifies the creation of PET tracers, allowing for real-time 3-D images of biological processes. This breakthrough has the potential to revolutionize drug development and disease diagnosis.
Recent studies support the use of C-11 choline positron emission tomography/computerized tomography (PET/CT) scans as a staging and potentially therapeutic tool for prostate cancer. The studies found that PET/CT scans can accurately diagnose localized disease recurrence, allowing for targeted treatment options.
The US Army has awarded a $1.5 million cooperative research agreement to Virginia Tech's Arlington Innovation Center for neuroimaging studies of human performance and sleep regulation. The project aims to use advanced imaging techniques to better understand the brain's role in sleep, stress, and mood.
Novel imaging agents detectable by PET imaging may visualize tumors in their earliest stages, enabling early detection and treatment of cancer. The compounds target COX-2, an enzyme found in inflammatory lesions and tumors.
Advanced PET scans can identify aggressive tumors and predict patient prognosis, potentially intensifying treatment for patients with locally advanced lung cancer. The study found a strong correlation between radiation dose intensity and local control of the cancer.
Researchers at the University of Strathclyde have created the brightest gamma ray beam ever made, more than a thousand billion times brighter than the sun. This breakthrough could lead to new medical imaging and radiotherapy techniques, as well as improved monitoring of nuclear waste.
Researchers have discovered that the vaccinia virus construct GLV-1h153 can be used to image and treat pancreatic cancer. The study found that hNIS-mediated radiouptake noninvasively imaged with PET provided information into tumor therapeutic response.
The Ohio Third Frontier Commission has awarded $2.5 million to advance two significant imaging research projects at the Philips Healthcare Global Advanced Imaging Innovation Center, a collaboration among University Hospitals Case Medical Center and Case Western Reserve University.
A new study by the Centre for Addiction and Mental Health found that heavy smokers who quit experience an increase in MAO-A levels, a mood-related brain protein. This finding may explain why heavy smokers are at high risk for clinical depression and provides potential targets to prevent sad mood during cigarette withdrawal.
The studies focus on positron emission tomography (PET) to differentiate between types of dementia and identify pharmaceuticals to slow dementia progression. PET scores provide a valid biomarker for monitoring Alzheimer's disease progression.
The investigational amyloid imaging agent [18F]Flutemetamol showed highly consistent image interpretation and comparable in vitro binding to Pittsburgh Compound-B, according to recent clinical research data. Flutemetamol is being studied for the detection of beta amyloid using PET brain scans.
A new PET imaging technique using [11C]erlotinib may help doctors identify lung cancers that respond well to tyrosine kinase inhibitors (TKIs), enabling personalized therapy. The test showed significantly higher tracer uptake in tumors with activating EGFR mutations, indicating a potential non-invasive predictive marker.
Joanna Fowler, a senior chemist at Brookhaven Lab, has been chosen to receive the Distinguished Women in Chemistry/Chemical Engineering Award. Her research focuses on developing radiotracers to measure changes in brain circuits disrupted by drug addiction and other brain diseases.
The study presents promising results for the clinical use of a new integrated PET/MRI system, which provides diagnostic information on soft tissues and physiological functions. The technology has been shown to be comparable in detecting cancerous tumors as conventional PET/CT methods.
Researchers combined two molecular imaging agents to create a powerful new tool for acquiring information about the extent of a patient's cancer. The results showed that combined 18F NaF and 18F FDG PET/CT imaging provided good-quality imaging of both skeletal and extra-skeletal malignant lesions from various cancers.
A study found that non-gated PET imaging with 4D computed tomography can produce more accurate tumor imaging for patients with irregular breathing. This approach may improve overall accuracy of tumor detection and inform clinicians about appropriate treatments.
Researchers found that PET/CT imaging with the radiotracer 18F-FDG successfully detected 84% of benign and malignant tumors in patients with adnexal masses. This technology helps predict cancer stage and provide better treatment options for women diagnosed with ovarian cancer.
A study introduced at SNM's 58th Annual Meeting found that 4D PET imaging using state-of-the-art image reconstruction and motion correction significantly improves cancer detection. This method provides clearer images, especially for small lesions, allowing for more accurate diagnosis and better treatment planning.
A new molecular imaging agent has been developed to detect tumor angiogenesis, a process of rapid blood vessel growth associated with malignant cancers. The agent, which targets the CD105 protein biomarker, shows promising results in early studies, including high uptake by tumors in mice.
A new imaging agent called 18F FPPRGD2 targets breast tumor development by detecting angiogenesis, a process that forms new blood vessels in tissues. This allows for better clinical decisions and earlier identification of patients who are ideal candidates for aggressive therapies.
A recent study published in The Journal of Nuclear Medicine found that PET scans can help determine earlier if treatment for tuberculosis is working or if the disease is multidrug-resistant. This technology has the potential to become a valuable clinical adjunct to genotypic and phenotypic tests, improving patient outcomes.
Researchers found that combining CT and FDG-PET images resulted in a change in tumor delineation in one out of three patients, leading to adjusted treatments in 10% of cases. This improvement was particularly notable in patients with dental inlays, where the primary tumor was not visible on CT scans alone.
A miniature, portable PET scanner has been developed to study brain function and behavior in rats while they are awake and moving freely. This breakthrough technology, dubbed RatCAP, uses a wearable design that counterbalances with springs and motion stabilizers, allowing animals significant freedom of movement.
Researchers found significant improvements in lesion detection with whole-body TOF FDG PET scans, particularly in larger patients and shorter studies. TOF scans yielded better image signal-to-noise due to travel time consideration, reducing scanning time and patient motion.
Researchers have developed methods to store billions of positrons for hours or more and cool them to low temperatures to study their properties. The largest trap for low-energy positrons is being built, capable of storing trillions of antimatter particles.
A new venue for imaging tests has been inaugurated for the PESA study, aiming to improve early detection and prevention of cardiovascular disorders. The research aims to identify risk factors and daily habits influencing atherosclerosis development.
A new study uses PET scans to image metabolic changes in thyroid cancer patients treated with vandetanib, a protein kinase inhibitor. The findings show that PET imaging can help define the therapy response and identify potential markers of treatment efficacy.
Researchers develop molecular imaging procedure to detect beta-amyloid in brains of individuals with Alzheimer's disease, increasing clinical diagnosis accuracy. The study shows a correlation between florbetapir-PET images and presence and quantity of beta-amyloid pathology at autopsy.
Researchers used PET scans to evaluate cognitive dysfunction in children with fever-induced refractory epileptic encephalopathy (FIRES), finding significant brain impairment. The study identified frontotemporal dysfunction as the cause of cognitive deterioration, paving the way for more accurate diagnosis and treatment.
A Swedish case study reveals how Alzheimer's disease progresses, with high amyloid plaque levels at early stages and declining brain energy. The discovery sheds light on the role of nicotinic receptors and neuroinflammation in the disease, offering new insights for diagnosis and treatment.
A study found that using true whole-body field view in PET/CT imaging can lead to more accurate staging and restaging of cancer patients. This increased accuracy can result in changes to treatment plans and the selection of biopsy sites, ultimately reducing unnecessary invasive procedures.
Jacob Hooker, a Brookhaven National Laboratory assistant chemist, received the Presidential Early Career Award for Scientists and Engineers. He was recognized for his research on radiochemistry and biomedical imaging, as well as his efforts to mentor and outreach to the community.
A new study reveals that men are up to twice as likely to develop alcoholism as women, with increased dopamine release in the brain contributing to this difference. The study found that men had greater dopamine release than women after consuming an alcoholic drink, which may contribute to the initial reinforcing properties of alcohol a...
SPADnet aims to create a new generation of smart image sensors for photon-starved biomedical applications, enabling scalable and efficient imaging. The project will develop ring-assembly modules for Positron Emission Tomography (PET) imaging and carry out performance tests in a PET evaluation system.
Two newer breast imaging technologies, BSGI and PEM, have been approved for clinical use despite higher cancer risks. The lifetime risk of radiation-induced cancer from BSGI and PEM exams are significantly higher than digital mammography, with estimated risks ranging from 20 to 30 times higher.
Researchers developed a novel 3D imaging approach that combines CT images with conventional ablation techniques to improve the accuracy of ventricular tachycardia treatment. The new method successfully predicted areas of abnormal electrical activity in 81.7% of heart segments analyzed.
Researchers at Risø National Laboratory are producing radioisotopes for medical diagnostics and therapy, as well as research and development of new technologies. The production has increased significantly due to growing demand from PET-CT scanning, with seven cyclotrons operating in Denmark.
The meeting showcased groundbreaking research and development worldwide in molecular imaging and nuclear medicine, with a focus on using molecular imaging to understand disease mechanisms and improve patient health. Key findings included advances in Alzheimer's disease identification and recurrent prostate cancer detection.
Researchers at the University of Granada have created a new system for early diagnosis of Alzheimer's disease using processed images. The system achieved an impressive 90% success rate in identifying patients with Alzheimer's disease.
Chester A. Mathis receives SNM's 2010 Aebersold Award for his groundbreaking work on early detection in Alzheimer's disease using positron emission tomography (PET) imaging techniques. This recognition acknowledges the significant contributions of Dr. Mathis to advancing molecular imaging and nuclear medicine.
Researchers developed a non-invasive imaging technique combining PET and CT scans without bowel preparation, detecting all significant polyps found by colonoscopy. Patients preferred this method over colonoscopy due to its comfort and lack of sedation.
The VECTor device combines microPET and microSPECT techniques to provide higher resolution and enable simultaneous imaging. This allows for more detailed analysis of cell function and disease mechanisms in experimental animal models.